Pro-Dex, Inc. (NASDAQ: PDEX) Stock Competitors & Peer Comparison
See PDEX's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Medical - Instruments & Supplies Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for PDEX and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| PDEX | $66.94 | +0.07% | 213.7M | 23.57 | $2.84 | N/A |
| ISRG | $397.72 | +1.67% | 140.5B | 41.34 | $9.62 | N/A |
| BDXA | $59.24 | -2.24% | 55.9B | 45.70 | $1.30 | +2.00% |
| BDX | $187.60 | +3.78% | 51.7B | 14.43 | $13.00 | +2.00% |
| MDLN | $33.91 | -0.62% | 28.7B | 24.85 | $1.36 | N/A |
| WST | $352.79 | +1.79% | 24.8B | 44.29 | $7.97 | +0.25% |
| HOLX | $76.01 | +0.00% | 17B | 31.54 | $2.41 | N/A |
| SOLV | $87.81 | +0.41% | 15.2B | 12.37 | $7.10 | N/A |
| COO | $76.73 | +1.28% | 15B | 16.83 | $4.56 | N/A |
| BAX | $26.64 | +2.70% | 13.8B | 12.82 | $2.08 | +0.75% |
Stock Comparison
Intuitive Surgical, Inc. (NASDAQ: ISRG)
PDEX vs ISRG Comparison August 2026
Pro-Dex, Inc. (NASDAQ: PDEX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 213.7M. In comparison, ISRG has a market cap of 140.5B. Regarding current trading prices, PDEX is priced at $66.94 on the NASDAQ, while ISRG trades at $397.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 23.57, whereas ISRG's P/E ratio is 41.34. In terms of profitability, PDEX's ROE is +0.29%, compared to ISRG's ROE of +0.18%. Regarding short-term risk, PDEX is more volatile compared to ISRG. This indicates higher risk in terms of short-term price fluctuations for PDEX.Check ISRG's competition here
Becton, Dickinson and Company (NYSE: BDXA)
PDEX vs BDXA Comparison August 2026
Pro-Dex, Inc. (NASDAQ: PDEX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 213.7M. In comparison, BDXA has a market cap of 55.9B. Regarding current trading prices, PDEX is priced at $66.94 on the NASDAQ, while BDXA trades at $59.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 23.57, whereas BDXA's P/E ratio is 45.70. In terms of profitability, PDEX's ROE is +0.29%, compared to BDXA's ROE of +0.04%. Regarding short-term risk, PDEX is less volatile compared to BDXA. This indicates lower risk in terms of short-term price fluctuations for PDEX.Check BDXA's competition here
Becton, Dickinson and Company (NYSE: BDX)
PDEX vs BDX Comparison August 2026
Pro-Dex, Inc. (NASDAQ: PDEX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 213.7M. In comparison, BDX has a market cap of 51.7B. Regarding current trading prices, PDEX is priced at $66.94 on the NASDAQ, while BDX trades at $187.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 23.57, whereas BDX's P/E ratio is 14.43. In terms of profitability, PDEX's ROE is +0.29%, compared to BDX's ROE of +0.04%. Regarding short-term risk, PDEX is more volatile compared to BDX. This indicates higher risk in terms of short-term price fluctuations for PDEX.Check BDX's competition here
Medline Inc. (NASDAQ: MDLN)
PDEX vs MDLN Comparison August 2026
Pro-Dex, Inc. (NASDAQ: PDEX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 213.7M. In comparison, MDLN has a market cap of 28.7B. Regarding current trading prices, PDEX is priced at $66.94 on the NASDAQ, while MDLN trades at $33.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 23.57, whereas MDLN's P/E ratio is 24.85. In terms of profitability, PDEX's ROE is +0.29%, compared to MDLN's ROE of +0.05%. Regarding short-term risk, PDEX is more volatile compared to MDLN. This indicates higher risk in terms of short-term price fluctuations for PDEX.Check MDLN's competition here
West Pharmaceutical Services, Inc. (NYSE: WST)
PDEX vs WST Comparison August 2026
Pro-Dex, Inc. (NASDAQ: PDEX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 213.7M. In comparison, WST has a market cap of 24.8B. Regarding current trading prices, PDEX is priced at $66.94 on the NASDAQ, while WST trades at $352.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 23.57, whereas WST's P/E ratio is 44.29. In terms of profitability, PDEX's ROE is +0.29%, compared to WST's ROE of +0.19%. Regarding short-term risk, PDEX is more volatile compared to WST. This indicates higher risk in terms of short-term price fluctuations for PDEX.Check WST's competition here
Hologic, Inc. (NASDAQ: HOLX)
PDEX vs HOLX Comparison August 2026
Pro-Dex, Inc. (NASDAQ: PDEX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 213.7M. In comparison, HOLX has a market cap of 17B. Regarding current trading prices, PDEX is priced at $66.94 on the NASDAQ, while HOLX trades at $76.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 23.57, whereas HOLX's P/E ratio is 31.54. In terms of profitability, PDEX's ROE is +0.29%, compared to HOLX's ROE of +0.11%. Regarding short-term risk, PDEX is more volatile compared to HOLX. This indicates higher risk in terms of short-term price fluctuations for PDEX.Check HOLX's competition here
Solventum Corporation (NYSE: SOLV)
PDEX vs SOLV Comparison August 2026
Pro-Dex, Inc. (NASDAQ: PDEX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 213.7M. In comparison, SOLV has a market cap of 15.2B. Regarding current trading prices, PDEX is priced at $66.94 on the NASDAQ, while SOLV trades at $87.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 23.57, whereas SOLV's P/E ratio is 12.37. In terms of profitability, PDEX's ROE is +0.29%, compared to SOLV's ROE of +0.29%. Regarding short-term risk, PDEX is more volatile compared to SOLV. This indicates higher risk in terms of short-term price fluctuations for PDEX.Check SOLV's competition here
The Cooper Companies, Inc. (NASDAQ: COO)
PDEX vs COO Comparison August 2026
Pro-Dex, Inc. (NASDAQ: PDEX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 213.7M. In comparison, COO has a market cap of 15B. Regarding current trading prices, PDEX is priced at $66.94 on the NASDAQ, while COO trades at $76.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 23.57, whereas COO's P/E ratio is 16.83. In terms of profitability, PDEX's ROE is +0.29%, compared to COO's ROE of +0.03%. Regarding short-term risk, PDEX is more volatile compared to COO. This indicates higher risk in terms of short-term price fluctuations for PDEX.Check COO's competition here
Baxter International Inc. (NYSE: BAX)
PDEX vs BAX Comparison August 2026
Pro-Dex, Inc. (NASDAQ: PDEX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 213.7M. In comparison, BAX has a market cap of 13.8B. Regarding current trading prices, PDEX is priced at $66.94 on the NASDAQ, while BAX trades at $26.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 23.57, whereas BAX's P/E ratio is 12.82. In terms of profitability, PDEX's ROE is +0.29%, compared to BAX's ROE of -0.17%. Regarding short-term risk, PDEX is more volatile compared to BAX. This indicates higher risk in terms of short-term price fluctuations for PDEX.Check BAX's competition here
Becton, Dickinson and Company (NYSE: BDXB)
PDEX vs BDXB Comparison August 2026
Pro-Dex, Inc. (NASDAQ: PDEX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 213.7M. In comparison, BDXB has a market cap of 13.7B. Regarding current trading prices, PDEX is priced at $66.94 on the NASDAQ, while BDXB trades at $48.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 23.57, whereas BDXB's P/E ratio is 7.60. In terms of profitability, PDEX's ROE is +0.29%, compared to BDXB's ROE of +0.04%. Regarding short-term risk, PDEX is more volatile compared to BDXB. This indicates higher risk in terms of short-term price fluctuations for PDEX.Check BDXB's competition here
Repligen Corporation (NASDAQ: RGEN)
PDEX vs RGEN Comparison August 2026
Pro-Dex, Inc. (NASDAQ: PDEX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 213.7M. In comparison, RGEN has a market cap of 10B. Regarding current trading prices, PDEX is priced at $66.94 on the NASDAQ, while RGEN trades at $176.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 23.57, whereas RGEN's P/E ratio is 97.98. In terms of profitability, PDEX's ROE is +0.29%, compared to RGEN's ROE of +0.02%. Regarding short-term risk, PDEX is less volatile compared to RGEN. This indicates lower risk in terms of short-term price fluctuations for PDEX.Check RGEN's competition here
Avantor, Inc. (NYSE: AVTR)
PDEX vs AVTR Comparison August 2026
Pro-Dex, Inc. (NASDAQ: PDEX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 213.7M. In comparison, AVTR has a market cap of 9.5B. Regarding current trading prices, PDEX is priced at $66.94 on the NASDAQ, while AVTR trades at $13.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 23.57, whereas AVTR's P/E ratio is 16.44. In terms of profitability, PDEX's ROE is +0.29%, compared to AVTR's ROE of -0.10%. Regarding short-term risk, PDEX is less volatile compared to AVTR. This indicates lower risk in terms of short-term price fluctuations for PDEX.Check AVTR's competition here
AptarGroup, Inc. (NYSE: ATR)
PDEX vs ATR Comparison August 2026
Pro-Dex, Inc. (NASDAQ: PDEX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 213.7M. In comparison, ATR has a market cap of 8.5B. Regarding current trading prices, PDEX is priced at $66.94 on the NASDAQ, while ATR trades at $132.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 23.57, whereas ATR's P/E ratio is 23.24. In terms of profitability, PDEX's ROE is +0.29%, compared to ATR's ROE of +0.14%. Regarding short-term risk, PDEX is more volatile compared to ATR. This indicates higher risk in terms of short-term price fluctuations for PDEX.Check ATR's competition here
Bausch + Lomb Corporation (NYSE: BLCO)
PDEX vs BLCO Comparison August 2026
Pro-Dex, Inc. (NASDAQ: PDEX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 213.7M. In comparison, BLCO has a market cap of 6.2B. Regarding current trading prices, PDEX is priced at $66.94 on the NASDAQ, while BLCO trades at $17.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 23.57, whereas BLCO's P/E ratio is 26.85. In terms of profitability, PDEX's ROE is +0.29%, compared to BLCO's ROE of -0.03%. Regarding short-term risk, PDEX is more volatile compared to BLCO. This indicates higher risk in terms of short-term price fluctuations for PDEX.Check BLCO's competition here
Teleflex Incorporated (NYSE: TFX)
PDEX vs TFX Comparison August 2026
Pro-Dex, Inc. (NASDAQ: PDEX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 213.7M. In comparison, TFX has a market cap of 6B. Regarding current trading prices, PDEX is priced at $66.94 on the NASDAQ, while TFX trades at $135.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 23.57, whereas TFX's P/E ratio is 15.54. In terms of profitability, PDEX's ROE is +0.29%, compared to TFX's ROE of -0.32%. Regarding short-term risk, PDEX is more volatile compared to TFX. This indicates higher risk in terms of short-term price fluctuations for PDEX.Check TFX's competition here
Stevanato Group S.p.A. (NYSE: STVN)
PDEX vs STVN Comparison August 2026
Pro-Dex, Inc. (NASDAQ: PDEX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 213.7M. In comparison, STVN has a market cap of 5.9B. Regarding current trading prices, PDEX is priced at $66.94 on the NASDAQ, while STVN trades at $21.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 23.57, whereas STVN's P/E ratio is 32.92. In terms of profitability, PDEX's ROE is +0.29%, compared to STVN's ROE of +0.09%. Regarding short-term risk, PDEX is more volatile compared to STVN. This indicates higher risk in terms of short-term price fluctuations for PDEX.Check STVN's competition here
Merit Medical Systems, Inc. (NASDAQ: MMSI)
PDEX vs MMSI Comparison August 2026
Pro-Dex, Inc. (NASDAQ: PDEX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 213.7M. In comparison, MMSI has a market cap of 5.5B. Regarding current trading prices, PDEX is priced at $66.94 on the NASDAQ, while MMSI trades at $91.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 23.57, whereas MMSI's P/E ratio is 23.52. In terms of profitability, PDEX's ROE is +0.29%, compared to MMSI's ROE of +0.09%. Regarding short-term risk, PDEX is more volatile compared to MMSI. This indicates higher risk in terms of short-term price fluctuations for PDEX.Check MMSI's competition here
ICU Medical, Inc. (NASDAQ: ICUI)
PDEX vs ICUI Comparison August 2026
Pro-Dex, Inc. (NASDAQ: PDEX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 213.7M. In comparison, ICUI has a market cap of 4.7B. Regarding current trading prices, PDEX is priced at $66.94 on the NASDAQ, while ICUI trades at $187.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 23.57, whereas ICUI's P/E ratio is 23.38. In terms of profitability, PDEX's ROE is +0.29%, compared to ICUI's ROE of +0.01%. Regarding short-term risk, PDEX is more volatile compared to ICUI. This indicates higher risk in terms of short-term price fluctuations for PDEX.Check ICUI's competition here
Envista Holdings Corp (NYSE: NVST)
PDEX vs NVST Comparison August 2026
Pro-Dex, Inc. (NASDAQ: PDEX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 213.7M. In comparison, NVST has a market cap of 4.5B. Regarding current trading prices, PDEX is priced at $66.94 on the NASDAQ, while NVST trades at $27.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 23.57, whereas NVST's P/E ratio is 18.93. In terms of profitability, PDEX's ROE is +0.29%, compared to NVST's ROE of +0.04%. Regarding short-term risk, PDEX is less volatile compared to NVST. This indicates lower risk in terms of short-term price fluctuations for PDEX.Check NVST's competition here
Pulse Biosciences, Inc. (NASDAQ: PLSE)
PDEX vs PLSE Comparison August 2026
Pro-Dex, Inc. (NASDAQ: PDEX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 213.7M. In comparison, PLSE has a market cap of 3.3B. Regarding current trading prices, PDEX is priced at $66.94 on the NASDAQ, while PLSE trades at $47.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 23.57, whereas PLSE's P/E ratio is -39.85. In terms of profitability, PDEX's ROE is +0.29%, compared to PLSE's ROE of -0.94%. Regarding short-term risk, PDEX is less volatile compared to PLSE. This indicates lower risk in terms of short-term price fluctuations for PDEX.Check PLSE's competition here
AtriCure, Inc. (NASDAQ: ATRC)
PDEX vs ATRC Comparison August 2026
Pro-Dex, Inc. (NASDAQ: PDEX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 213.7M. In comparison, ATRC has a market cap of 2.4B. Regarding current trading prices, PDEX is priced at $66.94 on the NASDAQ, while ATRC trades at $47.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 23.57, whereas ATRC's P/E ratio is 1478.57. In terms of profitability, PDEX's ROE is +0.29%, compared to ATRC's ROE of +0.02%. Regarding short-term risk, PDEX is more volatile compared to ATRC. This indicates higher risk in terms of short-term price fluctuations for PDEX.Check ATRC's competition here
DENTSPLY SIRONA Inc. (NASDAQ: XRAY)
PDEX vs XRAY Comparison August 2026
Pro-Dex, Inc. (NASDAQ: PDEX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 213.7M. In comparison, XRAY has a market cap of 2.2B. Regarding current trading prices, PDEX is priced at $66.94 on the NASDAQ, while XRAY trades at $11.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 23.57, whereas XRAY's P/E ratio is 7.71. In terms of profitability, PDEX's ROE is +0.29%, compared to XRAY's ROE of -0.40%. Regarding short-term risk, PDEX is less volatile compared to XRAY. This indicates lower risk in terms of short-term price fluctuations for PDEX.Check XRAY's competition here
LeMaitre Vascular, Inc. (NASDAQ: LMAT)
PDEX vs LMAT Comparison August 2026
Pro-Dex, Inc. (NASDAQ: PDEX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 213.7M. In comparison, LMAT has a market cap of 1.9B. Regarding current trading prices, PDEX is priced at $66.94 on the NASDAQ, while LMAT trades at $83.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 23.57, whereas LMAT's P/E ratio is 30.83. In terms of profitability, PDEX's ROE is +0.29%, compared to LMAT's ROE of +0.16%. Regarding short-term risk, PDEX is more volatile compared to LMAT. This indicates higher risk in terms of short-term price fluctuations for PDEX.Check LMAT's competition here
BioLife Solutions, Inc. (NASDAQ: BLFS)
PDEX vs BLFS Comparison August 2026
Pro-Dex, Inc. (NASDAQ: PDEX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 213.7M. In comparison, BLFS has a market cap of 1.8B. Regarding current trading prices, PDEX is priced at $66.94 on the NASDAQ, while BLFS trades at $36.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 23.57, whereas BLFS's P/E ratio is -172.56. In terms of profitability, PDEX's ROE is +0.29%, compared to BLFS's ROE of +0.13%. Regarding short-term risk, PDEX is more volatile compared to BLFS. This indicates higher risk in terms of short-term price fluctuations for PDEX.Check BLFS's competition here
Azenta, Inc. (NASDAQ: AZTA)
PDEX vs AZTA Comparison August 2026
Pro-Dex, Inc. (NASDAQ: PDEX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 213.7M. In comparison, AZTA has a market cap of 1.6B. Regarding current trading prices, PDEX is priced at $66.94 on the NASDAQ, while AZTA trades at $35.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 23.57, whereas AZTA's P/E ratio is 84.81. In terms of profitability, PDEX's ROE is +0.29%, compared to AZTA's ROE of -0.08%. Regarding short-term risk, PDEX is less volatile compared to AZTA. This indicates lower risk in terms of short-term price fluctuations for PDEX.Check AZTA's competition here
Kestra Medical Technologies, Ltd. (NASDAQ: KMTS)
PDEX vs KMTS Comparison August 2026
Pro-Dex, Inc. (NASDAQ: PDEX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 213.7M. In comparison, KMTS has a market cap of 1.6B. Regarding current trading prices, PDEX is priced at $66.94 on the NASDAQ, while KMTS trades at $27.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 23.57, whereas KMTS's P/E ratio is -11.83. In terms of profitability, PDEX's ROE is +0.29%, compared to KMTS's ROE of -0.59%. Regarding short-term risk, PDEX is less volatile compared to KMTS. This indicates lower risk in terms of short-term price fluctuations for PDEX.Check KMTS's competition here
STAAR Surgical Company (NASDAQ: STAA)
PDEX vs STAA Comparison August 2026
Pro-Dex, Inc. (NASDAQ: PDEX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 213.7M. In comparison, STAA has a market cap of 1.2B. Regarding current trading prices, PDEX is priced at $66.94 on the NASDAQ, while STAA trades at $24.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 23.57, whereas STAA's P/E ratio is 43.26. In terms of profitability, PDEX's ROE is +0.29%, compared to STAA's ROE of +0.01%. Regarding short-term risk, PDEX is less volatile compared to STAA. This indicates lower risk in terms of short-term price fluctuations for PDEX.Check STAA's competition here
QuidelOrtho Corporation (NASDAQ: QDEL)
PDEX vs QDEL Comparison August 2026
Pro-Dex, Inc. (NASDAQ: PDEX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 213.7M. In comparison, QDEL has a market cap of 941M. Regarding current trading prices, PDEX is priced at $66.94 on the NASDAQ, while QDEL trades at $13.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 23.57, whereas QDEL's P/E ratio is 10.30. In terms of profitability, PDEX's ROE is +0.29%, compared to QDEL's ROE of -0.55%. Regarding short-term risk, PDEX is less volatile compared to QDEL. This indicates lower risk in terms of short-term price fluctuations for PDEX.Check QDEL's competition here
Atrion Corporation (NASDAQ: ATRI)
PDEX vs ATRI Comparison August 2026
Pro-Dex, Inc. (NASDAQ: PDEX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 213.7M. In comparison, ATRI has a market cap of 809.4M. Regarding current trading prices, PDEX is priced at $66.94 on the NASDAQ, while ATRI trades at $459.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 23.57, whereas ATRI's P/E ratio is 64.50. In terms of profitability, PDEX's ROE is +0.29%, compared to ATRI's ROE of +0.08%. Regarding short-term risk, PDEX is more volatile compared to ATRI. This indicates higher risk in terms of short-term price fluctuations for PDEX.Check ATRI's competition here
AngioDynamics, Inc. (NASDAQ: ANGO)
PDEX vs ANGO Comparison August 2026
Pro-Dex, Inc. (NASDAQ: PDEX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 213.7M. In comparison, ANGO has a market cap of 664.2M. Regarding current trading prices, PDEX is priced at $66.94 on the NASDAQ, while ANGO trades at $16.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 23.57, whereas ANGO's P/E ratio is -41.21. In terms of profitability, PDEX's ROE is +0.29%, compared to ANGO's ROE of -0.21%. Regarding short-term risk, PDEX is more volatile compared to ANGO. This indicates higher risk in terms of short-term price fluctuations for PDEX.Check ANGO's competition here
Anbio Biotechnology Class A Ordinary Shares (NASDAQ: NNNN)
PDEX vs NNNN Comparison August 2026
Pro-Dex, Inc. (NASDAQ: PDEX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 213.7M. In comparison, NNNN has a market cap of 366.5M. Regarding current trading prices, PDEX is priced at $66.94 on the NASDAQ, while NNNN trades at $7.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 23.57, whereas NNNN's P/E ratio is 120.66. In terms of profitability, PDEX's ROE is +0.29%, compared to NNNN's ROE of +0.27%. Regarding short-term risk, PDEX is less volatile compared to NNNN. This indicates lower risk in terms of short-term price fluctuations for PDEX.Check NNNN's competition here
Sanara MedTech Inc. (NASDAQ: SMTI)
PDEX vs SMTI Comparison August 2026
Pro-Dex, Inc. (NASDAQ: PDEX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 213.7M. In comparison, SMTI has a market cap of 315.1M. Regarding current trading prices, PDEX is priced at $66.94 on the NASDAQ, while SMTI trades at $34.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 23.57, whereas SMTI's P/E ratio is -571.33. In terms of profitability, PDEX's ROE is +0.29%, compared to SMTI's ROE of -4.74%. Regarding short-term risk, PDEX is more volatile compared to SMTI. This indicates higher risk in terms of short-term price fluctuations for PDEX.Check SMTI's competition here
OraSure Technologies, Inc. (NASDAQ: OSUR)
PDEX vs OSUR Comparison August 2026
Pro-Dex, Inc. (NASDAQ: PDEX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 213.7M. In comparison, OSUR has a market cap of 258.2M. Regarding current trading prices, PDEX is priced at $66.94 on the NASDAQ, while OSUR trades at $3.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 23.57, whereas OSUR's P/E ratio is -6.82. In terms of profitability, PDEX's ROE is +0.29%, compared to OSUR's ROE of -0.15%. Regarding short-term risk, PDEX is similarly volatile compared to OSUR. This indicates similar risk in terms of short-term price fluctuations for PDEX.Check OSUR's competition here
InfuSystem Holdings, Inc. (AMEX: INFU)
PDEX vs INFU Comparison August 2026
Pro-Dex, Inc. (NASDAQ: PDEX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 213.7M. In comparison, INFU has a market cap of 245.8M. Regarding current trading prices, PDEX is priced at $66.94 on the NASDAQ, while INFU trades at $12.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 23.57, whereas INFU's P/E ratio is 29.71. In terms of profitability, PDEX's ROE is +0.29%, compared to INFU's ROE of +0.15%. Regarding short-term risk, PDEX is more volatile compared to INFU. This indicates higher risk in terms of short-term price fluctuations for PDEX.Check INFU's competition here
Utah Medical Products, Inc. (NASDAQ: UTMD)
PDEX vs UTMD Comparison August 2026
Pro-Dex, Inc. (NASDAQ: PDEX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 213.7M. In comparison, UTMD has a market cap of 229.6M. Regarding current trading prices, PDEX is priced at $66.94 on the NASDAQ, while UTMD trades at $72.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 23.57, whereas UTMD's P/E ratio is 21.34. In terms of profitability, PDEX's ROE is +0.29%, compared to UTMD's ROE of +0.09%. Regarding short-term risk, PDEX is more volatile compared to UTMD. This indicates higher risk in terms of short-term price fluctuations for PDEX.Check UTMD's competition here
KORU Medical Systems, Inc. (NASDAQ: KRMD)
PDEX vs KRMD Comparison August 2026
Pro-Dex, Inc. (NASDAQ: PDEX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 213.7M. In comparison, KRMD has a market cap of 152.5M. Regarding current trading prices, PDEX is priced at $66.94 on the NASDAQ, while KRMD trades at $3.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 23.57, whereas KRMD's P/E ratio is -83.00. In terms of profitability, PDEX's ROE is +0.29%, compared to KRMD's ROE of -0.11%. Regarding short-term risk, PDEX is more volatile compared to KRMD. This indicates higher risk in terms of short-term price fluctuations for PDEX.Check KRMD's competition here
Microbot Medical Inc. (NASDAQ: MBOT)
PDEX vs MBOT Comparison August 2026
Pro-Dex, Inc. (NASDAQ: PDEX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 213.7M. In comparison, MBOT has a market cap of 70.6M. Regarding current trading prices, PDEX is priced at $66.94 on the NASDAQ, while MBOT trades at $1.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 23.57, whereas MBOT's P/E ratio is -5.96. In terms of profitability, PDEX's ROE is +0.29%, compared to MBOT's ROE of -0.22%. Regarding short-term risk, PDEX is less volatile compared to MBOT. This indicates lower risk in terms of short-term price fluctuations for PDEX.Check MBOT's competition here
Akoya Biosciences, Inc. (NASDAQ: AKYA)
PDEX vs AKYA Comparison August 2026
Pro-Dex, Inc. (NASDAQ: PDEX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 213.7M. In comparison, AKYA has a market cap of 64.4M. Regarding current trading prices, PDEX is priced at $66.94 on the NASDAQ, while AKYA trades at $1.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 23.57, whereas AKYA's P/E ratio is -1.34. In terms of profitability, PDEX's ROE is +0.29%, compared to AKYA's ROE of -1.80%. Regarding short-term risk, PDEX is more volatile compared to AKYA. This indicates higher risk in terms of short-term price fluctuations for PDEX.Check AKYA's competition here
Daxor Corporation (NASDAQ: DXR)
PDEX vs DXR Comparison August 2026
Pro-Dex, Inc. (NASDAQ: PDEX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 213.7M. In comparison, DXR has a market cap of 60.1M. Regarding current trading prices, PDEX is priced at $66.94 on the NASDAQ, while DXR trades at $10.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 23.57, whereas DXR's P/E ratio is 5.67. In terms of profitability, PDEX's ROE is +0.29%, compared to DXR's ROE of +0.22%. Regarding short-term risk, PDEX is more volatile compared to DXR. This indicates higher risk in terms of short-term price fluctuations for PDEX.Check DXR's competition here
SkyAI, Inc. (NASDAQ: STSS)
PDEX vs STSS Comparison August 2026
Pro-Dex, Inc. (NASDAQ: PDEX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 213.7M. In comparison, STSS has a market cap of 53.7M. Regarding current trading prices, PDEX is priced at $66.94 on the NASDAQ, while STSS trades at $1.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 23.57, whereas STSS's P/E ratio is -0.02. In terms of profitability, PDEX's ROE is +0.29%, compared to STSS's ROE of -1.54%. Regarding short-term risk, PDEX is less volatile compared to STSS. This indicates lower risk in terms of short-term price fluctuations for PDEX.Check STSS's competition here
Nephros, Inc. (NASDAQ: NEPH)
PDEX vs NEPH Comparison August 2026
Pro-Dex, Inc. (NASDAQ: PDEX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 213.7M. In comparison, NEPH has a market cap of 51.7M. Regarding current trading prices, PDEX is priced at $66.94 on the NASDAQ, while NEPH trades at $4.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 23.57, whereas NEPH's P/E ratio is 79.33. In terms of profitability, PDEX's ROE is +0.29%, compared to NEPH's ROE of +0.16%. Regarding short-term risk, PDEX is less volatile compared to NEPH. This indicates lower risk in terms of short-term price fluctuations for PDEX.Check NEPH's competition here
Singular Genomics Systems, Inc. (NASDAQ: OMIC)
PDEX vs OMIC Comparison August 2026
Pro-Dex, Inc. (NASDAQ: PDEX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 213.7M. In comparison, OMIC has a market cap of 50.8M. Regarding current trading prices, PDEX is priced at $66.94 on the NASDAQ, while OMIC trades at $20.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 23.57, whereas OMIC's P/E ratio is -0.58. In terms of profitability, PDEX's ROE is +0.29%, compared to OMIC's ROE of -0.43%. Regarding short-term risk, PDEX is more volatile compared to OMIC. This indicates higher risk in terms of short-term price fluctuations for PDEX.Check OMIC's competition here
GlucoTrack, Inc. (NASDAQ: IGAP)
PDEX vs IGAP Comparison August 2026
Pro-Dex, Inc. (NASDAQ: PDEX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 213.7M. In comparison, IGAP has a market cap of 50.2M. Regarding current trading prices, PDEX is priced at $66.94 on the NASDAQ, while IGAP trades at $3.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 23.57, whereas IGAP's P/E ratio is -10.52. In terms of profitability, PDEX's ROE is +0.29%, compared to IGAP's ROE of +1.80%. Regarding short-term risk, PDEX is more volatile compared to IGAP. This indicates higher risk in terms of short-term price fluctuations for PDEX.Check IGAP's competition here
Precision Optics Corporation, Inc. (NASDAQ: POCI)
PDEX vs POCI Comparison August 2026
Pro-Dex, Inc. (NASDAQ: PDEX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 213.7M. In comparison, POCI has a market cap of 48.6M. Regarding current trading prices, PDEX is priced at $66.94 on the NASDAQ, while POCI trades at $4.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 23.57, whereas POCI's P/E ratio is -6.17. In terms of profitability, PDEX's ROE is +0.29%, compared to POCI's ROE of -0.37%. Regarding short-term risk, PDEX is less volatile compared to POCI. This indicates lower risk in terms of short-term price fluctuations for PDEX.Check POCI's competition here
Milestone Scientific Inc. (AMEX: MLSS)
PDEX vs MLSS Comparison August 2026
Pro-Dex, Inc. (NASDAQ: PDEX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 213.7M. In comparison, MLSS has a market cap of 42.4M. Regarding current trading prices, PDEX is priced at $66.94 on the NASDAQ, while MLSS trades at $0.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 23.57, whereas MLSS's P/E ratio is -7.99. In terms of profitability, PDEX's ROE is +0.29%, compared to MLSS's ROE of -1.49%. Regarding short-term risk, PDEX is less volatile compared to MLSS. This indicates lower risk in terms of short-term price fluctuations for PDEX.Check MLSS's competition here
Harvard Bioscience, Inc. (NASDAQ: HBIO)
PDEX vs HBIO Comparison August 2026
Pro-Dex, Inc. (NASDAQ: PDEX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 213.7M. In comparison, HBIO has a market cap of 31.9M. Regarding current trading prices, PDEX is priced at $66.94 on the NASDAQ, while HBIO trades at $7.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 23.57, whereas HBIO's P/E ratio is -19.67. In terms of profitability, PDEX's ROE is +0.29%, compared to HBIO's ROE of -0.92%. Regarding short-term risk, PDEX is more volatile compared to HBIO. This indicates higher risk in terms of short-term price fluctuations for PDEX.Check HBIO's competition here
SmileDirectClub, Inc. (NASDAQ: SDC)
PDEX vs SDC Comparison August 2026
Pro-Dex, Inc. (NASDAQ: PDEX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 213.7M. In comparison, SDC has a market cap of 29.1M. Regarding current trading prices, PDEX is priced at $66.94 on the NASDAQ, while SDC trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 23.57, whereas SDC's P/E ratio is -0.03. In terms of profitability, PDEX's ROE is +0.29%, compared to SDC's ROE of -1.96%. Regarding short-term risk, PDEX is less volatile compared to SDC. This indicates lower risk in terms of short-term price fluctuations for PDEX.Check SDC's competition here
Invacare Corporation (NYSE: IVC)
PDEX vs IVC Comparison August 2026
Pro-Dex, Inc. (NASDAQ: PDEX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 213.7M. In comparison, IVC has a market cap of 24.9M. Regarding current trading prices, PDEX is priced at $66.94 on the NASDAQ, while IVC trades at $0.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 23.57, whereas IVC's P/E ratio is -0.79. In terms of profitability, PDEX's ROE is +0.29%, compared to IVC's ROE of -0.46%. Regarding short-term risk, PDEX is less volatile compared to IVC. This indicates lower risk in terms of short-term price fluctuations for PDEX.Check IVC's competition here
Jin Medical International Ltd. (NASDAQ: ZJYL)
PDEX vs ZJYL Comparison August 2026
Pro-Dex, Inc. (NASDAQ: PDEX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 213.7M. In comparison, ZJYL has a market cap of 24.1M. Regarding current trading prices, PDEX is priced at $66.94 on the NASDAQ, while ZJYL trades at $3.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 23.57, whereas ZJYL's P/E ratio is 19.25. In terms of profitability, PDEX's ROE is +0.29%, compared to ZJYL's ROE of +0.04%. Regarding short-term risk, PDEX is less volatile compared to ZJYL. This indicates lower risk in terms of short-term price fluctuations for PDEX.Check ZJYL's competition here
Retractable Technologies, Inc. (AMEX: RVP)
PDEX vs RVP Comparison August 2026
Pro-Dex, Inc. (NASDAQ: PDEX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 213.7M. In comparison, RVP has a market cap of 21.7M. Regarding current trading prices, PDEX is priced at $66.94 on the NASDAQ, while RVP trades at $0.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 23.57, whereas RVP's P/E ratio is -2.20. In terms of profitability, PDEX's ROE is +0.29%, compared to RVP's ROE of -0.05%. Regarding short-term risk, PDEX is more volatile compared to RVP. This indicates higher risk in terms of short-term price fluctuations for PDEX.Check RVP's competition here
Regentis Biomaterials Ltd. (AMEX: RGNT)
PDEX vs RGNT Comparison August 2026
Pro-Dex, Inc. (NASDAQ: PDEX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 213.7M. In comparison, RGNT has a market cap of 15.6M. Regarding current trading prices, PDEX is priced at $66.94 on the NASDAQ, while RGNT trades at $2.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 23.57, whereas RGNT's P/E ratio is -0.09. In terms of profitability, PDEX's ROE is +0.29%, compared to RGNT's ROE of N/A. Regarding short-term risk, PDEX is less volatile compared to RGNT. This indicates lower risk in terms of short-term price fluctuations for PDEX.Check RGNT's competition here
Femasys Inc. (NASDAQ: FEMY)
PDEX vs FEMY Comparison August 2026
Pro-Dex, Inc. (NASDAQ: PDEX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 213.7M. In comparison, FEMY has a market cap of 7.9M. Regarding current trading prices, PDEX is priced at $66.94 on the NASDAQ, while FEMY trades at $2.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 23.57, whereas FEMY's P/E ratio is -7.21. In terms of profitability, PDEX's ROE is +0.29%, compared to FEMY's ROE of -2.26%. Regarding short-term risk, PDEX is less volatile compared to FEMY. This indicates lower risk in terms of short-term price fluctuations for PDEX.Check FEMY's competition here
NanoString Technologies, Inc. (NASDAQ: NSTG)
PDEX vs NSTG Comparison August 2026
Pro-Dex, Inc. (NASDAQ: PDEX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 213.7M. In comparison, NSTG has a market cap of 5.1M. Regarding current trading prices, PDEX is priced at $66.94 on the NASDAQ, while NSTG trades at $0.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 23.57, whereas NSTG's P/E ratio is -0.03. In terms of profitability, PDEX's ROE is +0.29%, compared to NSTG's ROE of -1.43%. Regarding short-term risk, PDEX is less volatile compared to NSTG. This indicates lower risk in terms of short-term price fluctuations for PDEX.Check NSTG's competition here
Lucyd, Inc (NASDAQ: LUCY)
PDEX vs LUCY Comparison August 2026
Pro-Dex, Inc. (NASDAQ: PDEX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 213.7M. In comparison, LUCY has a market cap of 4.4M. Regarding current trading prices, PDEX is priced at $66.94 on the NASDAQ, while LUCY trades at $0.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 23.57, whereas LUCY's P/E ratio is -0.41. In terms of profitability, PDEX's ROE is +0.29%, compared to LUCY's ROE of -0.89%. Regarding short-term risk, PDEX is less volatile compared to LUCY. This indicates lower risk in terms of short-term price fluctuations for PDEX.Check LUCY's competition here
Predictive Oncology Inc. (NASDAQ: POAI)
PDEX vs POAI Comparison August 2026
Pro-Dex, Inc. (NASDAQ: PDEX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 213.7M. In comparison, POAI has a market cap of 3.6M. Regarding current trading prices, PDEX is priced at $66.94 on the NASDAQ, while POAI trades at $4.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 23.57, whereas POAI's P/E ratio is -0.03. In terms of profitability, PDEX's ROE is +0.29%, compared to POAI's ROE of -21.19%. Regarding short-term risk, PDEX is less volatile compared to POAI. This indicates lower risk in terms of short-term price fluctuations for PDEX.Check POAI's competition here
NEXGEL, Inc. (NASDAQ: NXGL)
PDEX vs NXGL Comparison August 2026
Pro-Dex, Inc. (NASDAQ: PDEX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 213.7M. In comparison, NXGL has a market cap of 3.3M. Regarding current trading prices, PDEX is priced at $66.94 on the NASDAQ, while NXGL trades at $0.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 23.57, whereas NXGL's P/E ratio is -0.55. In terms of profitability, PDEX's ROE is +0.29%, compared to NXGL's ROE of -1.33%. Regarding short-term risk, PDEX is less volatile compared to NXGL. This indicates lower risk in terms of short-term price fluctuations for PDEX.Check NXGL's competition here
GlucoTrack, Inc. (NASDAQ: GCTK)
PDEX vs GCTK Comparison August 2026
Pro-Dex, Inc. (NASDAQ: PDEX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 213.7M. In comparison, GCTK has a market cap of 2.7M. Regarding current trading prices, PDEX is priced at $66.94 on the NASDAQ, while GCTK trades at $0.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 23.57, whereas GCTK's P/E ratio is -0.02. In terms of profitability, PDEX's ROE is +0.29%, compared to GCTK's ROE of -21.36%. Regarding short-term risk, PDEX is less volatile compared to GCTK. This indicates lower risk in terms of short-term price fluctuations for PDEX.Check GCTK's competition here
Meihua International Medical Technologies Co., Ltd. (NASDAQ: MHUA)
PDEX vs MHUA Comparison August 2026
Pro-Dex, Inc. (NASDAQ: PDEX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 213.7M. In comparison, MHUA has a market cap of 2.4M. Regarding current trading prices, PDEX is priced at $66.94 on the NASDAQ, while MHUA trades at $7.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 23.57, whereas MHUA's P/E ratio is 0.25. In terms of profitability, PDEX's ROE is +0.29%, compared to MHUA's ROE of +0.07%. Regarding short-term risk, PDEX is more volatile compared to MHUA. This indicates higher risk in terms of short-term price fluctuations for PDEX.Check MHUA's competition here
G Medical Innovations Holdings Ltd (NASDAQ: GMVD)
PDEX vs GMVD Comparison August 2026
Pro-Dex, Inc. (NASDAQ: PDEX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 213.7M. In comparison, GMVD has a market cap of 1.8M. Regarding current trading prices, PDEX is priced at $66.94 on the NASDAQ, while GMVD trades at $0.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 23.57, whereas GMVD's P/E ratio is -0.01. In terms of profitability, PDEX's ROE is +0.29%, compared to GMVD's ROE of +2.09%. Regarding short-term risk, PDEX is less volatile compared to GMVD. This indicates lower risk in terms of short-term price fluctuations for PDEX.Check GMVD's competition here
G Medical Innovations Holdings Ltd (NASDAQ: GMVDW)
PDEX vs GMVDW Comparison August 2026
Pro-Dex, Inc. (NASDAQ: PDEX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 213.7M. In comparison, GMVDW has a market cap of 1.8M. Regarding current trading prices, PDEX is priced at $66.94 on the NASDAQ, while GMVDW trades at $7.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 23.57, whereas GMVDW's P/E ratio is N/A. In terms of profitability, PDEX's ROE is +0.29%, compared to GMVDW's ROE of +2.09%. Regarding short-term risk, PDEX is less volatile compared to GMVDW. This indicates lower risk in terms of short-term price fluctuations for PDEX.Check GMVDW's competition here
NEXGEL, Inc. (NASDAQ: NXGLW)
PDEX vs NXGLW Comparison August 2026
Pro-Dex, Inc. (NASDAQ: PDEX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 213.7M. In comparison, NXGLW has a market cap of 1.5M. Regarding current trading prices, PDEX is priced at $66.94 on the NASDAQ, while NXGLW trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 23.57, whereas NXGLW's P/E ratio is -0.05. In terms of profitability, PDEX's ROE is +0.29%, compared to NXGLW's ROE of -1.33%. Regarding short-term risk, PDEX is less volatile compared to NXGLW. This indicates lower risk in terms of short-term price fluctuations for PDEX.Check NXGLW's competition here
Avinger, Inc. (NASDAQ: AVGR)
PDEX vs AVGR Comparison August 2026
Pro-Dex, Inc. (NASDAQ: PDEX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 213.7M. In comparison, AVGR has a market cap of 1.5M. Regarding current trading prices, PDEX is priced at $66.94 on the NASDAQ, while AVGR trades at $0.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 23.57, whereas AVGR's P/E ratio is -0.05. In terms of profitability, PDEX's ROE is +0.29%, compared to AVGR's ROE of +17.82%. Regarding short-term risk, PDEX is less volatile compared to AVGR. This indicates lower risk in terms of short-term price fluctuations for PDEX.Check AVGR's competition here
Lucyd, Inc (NASDAQ: LUCYW)
PDEX vs LUCYW Comparison August 2026
Pro-Dex, Inc. (NASDAQ: PDEX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 213.7M. In comparison, LUCYW has a market cap of 296.1K. Regarding current trading prices, PDEX is priced at $66.94 on the NASDAQ, while LUCYW trades at $0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 23.57, whereas LUCYW's P/E ratio is N/A. In terms of profitability, PDEX's ROE is +0.29%, compared to LUCYW's ROE of -0.89%. Regarding short-term risk, PDEX is less volatile compared to LUCYW. This indicates lower risk in terms of short-term price fluctuations for PDEX.Check LUCYW's competition here
Apria, Inc. (NASDAQ: APR)
PDEX vs APR Comparison August 2026
Pro-Dex, Inc. (NASDAQ: PDEX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 213.7M. In comparison, APR has a market cap of 0. Regarding current trading prices, PDEX is priced at $66.94 on the NASDAQ, while APR trades at $37.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 23.57, whereas APR's P/E ratio is 22.59. In terms of profitability, PDEX's ROE is +0.29%, compared to APR's ROE of +9.81%. Regarding short-term risk, PDEX is more volatile compared to APR. This indicates higher risk in terms of short-term price fluctuations for PDEX.Check APR's competition here
Hill-Rom Holdings, Inc. (NYSE: HRC)
PDEX vs HRC Comparison August 2026
Pro-Dex, Inc. (NASDAQ: PDEX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 213.7M. In comparison, HRC has a market cap of 0. Regarding current trading prices, PDEX is priced at $66.94 on the NASDAQ, while HRC trades at $155.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 23.57, whereas HRC's P/E ratio is 41.92. In terms of profitability, PDEX's ROE is +0.29%, compared to HRC's ROE of +0.14%. Regarding short-term risk, PDEX is more volatile compared to HRC. This indicates higher risk in terms of short-term price fluctuations for PDEX.Check HRC's competition here
IntriCon Corporation (NASDAQ: IIN)
PDEX vs IIN Comparison August 2026
Pro-Dex, Inc. (NASDAQ: PDEX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 213.7M. In comparison, IIN has a market cap of 0. Regarding current trading prices, PDEX is priced at $66.94 on the NASDAQ, while IIN trades at $24.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 23.57, whereas IIN's P/E ratio is 226.45. In terms of profitability, PDEX's ROE is +0.29%, compared to IIN's ROE of -0.00%. Regarding short-term risk, PDEX is more volatile compared to IIN. This indicates higher risk in terms of short-term price fluctuations for PDEX.Check IIN's competition here
Analogic Corporation (NASDAQ: ALOG)
PDEX vs ALOG Comparison August 2026
Pro-Dex, Inc. (NASDAQ: PDEX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 213.7M. In comparison, ALOG has a market cap of 0. Regarding current trading prices, PDEX is priced at $66.94 on the NASDAQ, while ALOG trades at $83.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 23.57, whereas ALOG's P/E ratio is 40.93. In terms of profitability, PDEX's ROE is +0.29%, compared to ALOG's ROE of -0.15%. Regarding short-term risk, PDEX is more volatile compared to ALOG. This indicates higher risk in terms of short-term price fluctuations for PDEX.Check ALOG's competition here
Invuity, Inc. (NASDAQ: IVTY)
PDEX vs IVTY Comparison August 2026
Pro-Dex, Inc. (NASDAQ: PDEX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 213.7M. In comparison, IVTY has a market cap of 0. Regarding current trading prices, PDEX is priced at $66.94 on the NASDAQ, while IVTY trades at $7.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 23.57, whereas IVTY's P/E ratio is -3.80. In terms of profitability, PDEX's ROE is +0.29%, compared to IVTY's ROE of -2.40%. Regarding short-term risk, PDEX is more volatile compared to IVTY. This indicates higher risk in terms of short-term price fluctuations for PDEX.Check IVTY's competition here
Antares Pharma, Inc. (NASDAQ: ATRS)
PDEX vs ATRS Comparison August 2026
Pro-Dex, Inc. (NASDAQ: PDEX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PDEX stands at 213.7M. In comparison, ATRS has a market cap of 0. Regarding current trading prices, PDEX is priced at $66.94 on the NASDAQ, while ATRS trades at $5.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PDEX currently has a P/E ratio of 23.57, whereas ATRS's P/E ratio is 14.95. In terms of profitability, PDEX's ROE is +0.29%, compared to ATRS's ROE of +0.31%. Regarding short-term risk, PDEX is more volatile compared to ATRS. This indicates higher risk in terms of short-term price fluctuations for PDEX.Check ATRS's competition here